Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
Mefloquine
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
The upper dosage value listed reflects the highest dose reported in available experience accounts rather than a formally established ceiling.
Subjective Effects
Pharmacology
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Harm Potential
Toxicity
Mefloquine is metabolized primarily through the liver, and impaired hepatic function may prolong elimination, resulting in higher plasma levels and increased risk of adverse reactions.
Mefloquine may cause abnormalities with heart rhythms visible on electrocardiograms, including QTc interval prolongation.
Mefloquine is classified as an agent causing muscle toxicity.
Mefloquine is an antimalarial medication used to prevent malaria and to treat the infection.
Psychosis Risk
Psychiatric effects include nightmares, visual and auditory hallucinations, anxiety, depression, unusual behavior, and suicidal ideations. The FDA added a boxed warning in 2013 regarding neuropsychiatric side effects that may persist for months to years after discontinuation or may be permanent. Central nervous system events requiring hospitalization occur in approximately 1 in 10,000 people taking mefloquine for prophylaxis, while milder events such as vivid dreams and insomnia affect up to 25% of users. Mefloquine is contraindicated in those with a history of psychiatric disorders.
Seizure Risk
Mefloquine reduces seizure threshold and neurological side effects include seizures. The drug is contraindicated in those with a previous history of seizures. Neurologic effects can occur at any time during use and may persist for months to years after discontinuation or become permanent.
History & Culture
Legality
By Country
References
Source Pages
Citations
- Prescription Drug List: Human Use. hpr-rps.hres.ca (n.d.). https://hpr-rps.hres.ca/pdl-phu.php1
- The Prescription Drug List: Access the list and notices. canada.ca (n.d.). https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/access-list-notices.html1
- Food and Drugs Act. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/f-27/section-29.1.html1
- Food and Drug Regulations. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._870/section-A.01.010.html1
- Food and Drug Regulations. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._870/section-C.01.041.html1
- Search results summary. health-products.canada.ca (n.d.). https://health-products.canada.ca/dpd-bdpp/search-fast-recherche-rapide?lang=eng&no=01242270011
- Product information. health-products.canada.ca (n.d.). https://health-products.canada.ca/dpd-bdpp/info?code=68334&lang=eng1
- Health Products (Therapeutic Products) Regulations 2016 — Second Schedule, Part 1. sso.agc.gov.sg (n.d.). https://sso.agc.gov.sg/SL/HPA2007-S329-2016?ProvIds=Sc2-1
- Health Products (Therapeutic Products) Regulations 2016 — regulation 11. sso.agc.gov.sg (n.d.). https://sso.agc.gov.sg/SL/HPA2007-S329-2016?ProvIds=pr11-1
- Reclassification process | Health Sciences Authority. hsa.gov.sg (n.d.). https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/variation-application/reclassification/apply-for-reclassification/1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Mefloquine article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.